Ilunocitinib has a high potency for inhibition of JAK1, JAK2, and tyrosine kinase 2 (TYK2) and has been developed as a treatment for allergic and atopic dermatitis (AD) in dogs one year of age or older [1]. This evidence concerns the gene TYK2 and atopic eczema.